Meeting
2024 ASCO Genitourinary Cancers Symposium
Evaluating outcomes of sacituzumab govitecan (SG) in patients with urothelial cancer (UC), previously treated with enfortumab vedotin (EV).
Authors
Evangelia Vlachou
Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD
Evangelia Vlachou , Burles Avner Johnson III, Noah M. Hahn , Kelli Rourke , David James McConkey , Jean H. Hoffman-Censits
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 567)
DOI
10.1200/JCO.2024.42.4_suppl.567
Abstract #
567
Poster Bd #
E16
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC).
First Author: Michal Sternschuss
Poster
2024 ASCO Genitourinary Cancers Symposium
Safety and efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial cancer: Real-world evidence from a European database.
First Author: Stefanie Zschaebitz
Poster
2024 ASCO Genitourinary Cancers Symposium
Impact of homologous recombination repair (HRR) or nucleotide excision repair (NER) deficiency on sensitivity to antibody drug conjugate (ADC) payloads in urothelial cancer.
First Author: Surish P Shanmugam
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC).
First Author: Anup Kasi